Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BOPA/ISOPP 2019 | Potential role of rituximab in mCRPC

Lisa Holle • 10 Oct 2019
BOPA/ISOPP 2019
Genitourinary Cancer Prostate Cancer Rituximab

Lisa Holle, PharmD, BCOP, FHOPA, University of Connecticut School of Pharmacy, Storrs, CT, reviews a recent case study of a patient with castrate-resistant prostate cancer who responded to treatment for a secondary folliular lymphoma following treatment with rituximab. This interview took place at the International Society of Oncology Pharmacy Practitioners (ISOPP) Symposium 2019, hosted by the British Oncology Pharmacy Association (BOPA), held in London, UK.

More from Lisa Holle

2:19
Can spinners improve understanding of adverse events in patients with cancer?
Lisa Holle • 10 Oct 2019

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals